The Life Sciences team advised Flagship Pioneering on a first-of-its-kind strategic partnership with the Cystic Fibrosis Foundation and Pioneering Medicines. The partnership will develop therapeutics that address the unmet needs of people living with cystic fibrosis by leveraging the innovations and teams of multiple Flagship-founded companies. Through this agreement, the Cystic Fibrosis Foundation has committed up to $110 million to Pioneering Medicines to bring forward multiple development candidates and develop these candidates to human proof of concept.
Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $200 billion in aggregate value.
Pioneering Medicines is a strategic initiative within Flagship Pioneering that is dedicated to conceiving and developing a broad portfolio of life-changing treatments by leveraging and expanding the use of Flagship’s innovations.
Through this collaborative agreement, Pioneering Medicines and the Cystic Fibrosis Foundation will partner with multiple companies within the Flagship ecosystem, leveraging emerging technologies including Tessera Therapeutics’ Gene WritingTM technology, targeted delivery modalities, and RNA technologies. The teams will work together to harness their unique technologies and develop individual asset companies specifically focused on potential treatments for cystic fibrosis.